DexCom Inc (DXCM)
Return on total capital
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Earnings before interest and tax (EBIT) (ttm) | US$ in thousands | 730,700 | 617,500 | 523,000 | 437,800 | 409,400 | 282,600 | 248,400 | 270,300 | 275,600 | 376,300 | 359,200 | 323,800 | 315,600 | 313,400 | 274,800 | 214,000 | 164,500 | -113,800 | -125,000 | -96,300 |
Long-term debt | US$ in thousands | 2,434,200 | 2,432,400 | 2,430,600 | 1,198,500 | 1,197,700 | 1,968,800 | 1,967,300 | 1,965,900 | 1,702,700 | 1,703,500 | 1,710,700 | 1,688,800 | 1,667,200 | 1,645,800 | 1,658,800 | 1,072,400 | 1,059,700 | 1,047,100 | 1,034,700 | 1,022,400 |
Total stockholders’ equity | US$ in thousands | 2,068,600 | 2,267,900 | 2,100,400 | 2,233,000 | 2,131,800 | 1,824,500 | 2,255,900 | 2,189,300 | 2,042,100 | 1,912,000 | 1,754,700 | 1,644,800 | 1,551,900 | 1,499,300 | 1,353,900 | 934,500 | 882,600 | 764,300 | 688,300 | 668,600 |
Return on total capital | 16.23% | 13.14% | 11.54% | 12.76% | 12.30% | 7.45% | 5.88% | 6.51% | 7.36% | 10.41% | 10.37% | 9.71% | 9.80% | 9.96% | 9.12% | 10.66% | 8.47% | -6.28% | -7.25% | -5.69% |
December 31, 2023 calculation
Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $730,700K ÷ ($2,434,200K + $2,068,600K)
= 16.23%
Over the past eight quarters, Dexcom Inc's return on total capital has shown a generally positive trend, with fluctuations. The return on total capital has ranged from 5.86% to 13.15%. The highest return was in Q4 2023 at 13.15%, demonstrating the company's ability to generate profits relative to its total capital employed. It was followed by Q3 2023 at 10.39%. This indicates that Dexcom Inc has been effectively utilizing its capital investment to generate returns for its stakeholders. However, there were slight decreases in Q2 2023 and Q1 2023 compared to the previous quarters. The consistency of positive returns over the quarters reflects Dexcom Inc's efficiency in deploying its capital to generate profits.
Peer comparison
Dec 31, 2023